^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Rui Lisheng (romiplostim biosimilar)

    i
    Other names: QL0911
    Associations

    News

    Trials
    Company:
    Qilu Pharma
    Drug class:
    Thrombopoietin receptor agonist
    Related drugs:
    Associations

    News

    Trials
    3d
    Single-center clinical study on the efficacy and safety of romiplostim N01 in promoting platelet engraftment after hematopoietic stem cell transplantation (ChiCTR2600116939)
    P=N/A, N=88, Not yet recruiting, The First Affiliated Hospital of Guilin Medical University; The First Affiliated Hospital of Guilin Medical University
    New trial
    |
    NKG2D (killer cell lectin like receptor K1)
    |
    Nplate (romiplostim) • Rui Lisheng (romiplostim biosimilar)
    3d
    A Single-Arm, Multicenter, Exploratory Study on the Efficacy and Safety of Romiplostim NO1 in Platelet Recovery After Autologous Hematopoietic Stem Cell Transplantation (ChiCTR2500114483)
    P=N/A, N=50, Not yet recruiting, The First Affiliated Hospital of Bengbu Medical University; The First Affiliated Hospital of Bengbu Medical University
    New trial
    |
    CD34 (CD34 molecule)
    |
    Nplate (romiplostim) • Rui Lisheng (romiplostim biosimilar)
    3d
    A prospective, single-arm study of romiplostim N01 for prevention of chemotherapy-induced thrombocytopenia in patients with non-Hodgkin's lymphoma (ChiCTR2600116402)
    P4, N=30, Not yet recruiting, Jiangxi Cancer Hospital; Jiangxi Cancer Hospital
    New P4 trial
    |
    Nplate (romiplostim) • Rui Lisheng (romiplostim biosimilar)
    3d
    A Multicenter, Single-Arm Study of Romiplostim N01 in Megakaryocytic Engraftment after Allogeneic Hematopoietic Stem Cell Transplantation for Bone Marrow Failure Diseases (ChiCTR2600116641)
    P4, N=35, Not yet recruiting, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University
    New P4 trial
    |
    Nplate (romiplostim) • Rui Lisheng (romiplostim biosimilar)
    19d
    A Study of Romiplostim N01 Plus IST vs. Placebo Plus IST for Treatment-Naive Severe Aplastic Anemia (clinicaltrials.gov)
    P3, N=210, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
    New P3 trial
    |
    cyclosporin A microemulsion • Nplate (romiplostim) • Rui Lisheng (romiplostim biosimilar)
    22d
    QL0911-302: QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia (clinicaltrials.gov)
    P2/3, N=235, Recruiting, Qilu Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rui Lisheng (romiplostim biosimilar)
    over1year
    Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia (clinicaltrials.gov)
    P2/3, N=63, Completed, Qilu Pharmaceutical Co., Ltd. | Recruiting --> Completed | Trial completion date: Jul 2023 --> Feb 2024 | Trial primary completion date: May 2023 --> Feb 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    Rui Lisheng (romiplostim biosimilar)
    over1year
    QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia (clinicaltrials.gov)
    P2/3, N=235, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
    New P2/3 trial
    |
    Rui Lisheng (romiplostim biosimilar)
    over2years
    Evaluating the Efficacy and Safety of QL0911 in Chemotherapy- Induced Thrombocytopenia (clinicaltrials.gov)
    P2/3, N=50, Completed, Qilu Pharmaceutical Co., Ltd.
    New P2/3 trial
    |
    Rui Lisheng (romiplostim biosimilar)